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Sarm1 deletion suppresses TDP-43-linked
motor neuron degeneration and cortical
spine loss
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Camille K. Hunt1, Ella Burchill1, Isobel Callaghan1, Andrea Loreto5, Heledd Brown-Wright6, Richard Mead6,
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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition that primarily affects the motor system
and shares many features with frontotemporal dementia (FTD). Evidence suggests that ALS is a ‘dying-back’ disease,
with peripheral denervation and axonal degeneration occurring before loss of motor neuron cell bodies. Distal to a
nerve injury, a similar pattern of axonal degeneration can be seen, which is mediated by an active axon destruction
mechanism called Wallerian degeneration. Sterile alpha and TIR motif-containing 1 (Sarm1) is a key gene in the
Wallerian pathway and its deletion provides long-term protection against both Wallerian degeneration and
Wallerian-like, non-injury induced axonopathy, a retrograde degenerative process that occurs in many
neurodegenerative diseases where axonal transport is impaired. Here, we explored whether Sarm1 signalling could
be a therapeutic target for ALS by deleting Sarm1 from a mouse model of ALS-FTD, a TDP-43Q331K, YFP-H double
transgenic mouse. Sarm1 deletion attenuated motor axon degeneration and neuromuscular junction denervation.
Motor neuron cell bodies were also significantly protected. Deletion of Sarm1 also attenuated loss of layer V
pyramidal neuronal dendritic spines in the primary motor cortex. Structural MRI identified the entorhinal cortex as
the most significantly atrophic region, and histological studies confirmed a greater loss of neurons in the entorhinal
cortex than in the motor cortex, suggesting a prominent FTD-like pattern of neurodegeneration in this transgenic
mouse model. Despite the reduction in neuronal degeneration, Sarm1 deletion did not attenuate age-related
behavioural deficits caused by TDP-43Q331K. However, Sarm1 deletion was associated with a significant increase in
the viability of male TDP-43Q331K mice, suggesting a detrimental role of Wallerian-like pathways in the earliest
stages of TDP-43Q331K-mediated neurodegeneration. Collectively, these results indicate that anti-SARM1 strategies
have therapeutic potential in ALS-FTD.
Keywords: Sterile alpha and TIR motif-containing protein 1, Amyotrophic lateral sclerosis, TAR DNA-binding protein
43, Wallerian degeneration, Axonal protection, Dendritic spines
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive and
ultimately fatal adult motor neuron disease that causes
inexorable paralysis of limb, bulbar and respiratory
muscles. Patients may also demonstrate cognitive deficits
in keeping with frontotemporal dementia (FTD). Current
disease modifying approaches for ALS have only a modest
effect on survival and new therapeutic agents are urgently
required. Targeting the earliest stages in the neurode-
generative process holds the greatest promise for thera-
peutic advances.
In ALS, pathological studies demonstrate early peripheral
denervation before ventral nerve root or motor neuronal
cell body loss suggesting that degeneration starts at the
nerve terminal and progresses retrogradely along the axon
[20]. Indeed, distal corticospinal tract inflammatory
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changes [8, 37] and giant axonal swellings have been
detected in spinal cords from ALS patients, suggesting
early distal axonal degeneration [15, 53]. Similarly, mu-
tant-SOD1 mice with ALS-like phenotypes exhibit
presymptomatic muscle denervation and terminal axonal
degeneration before anterior horn cell loss [20, 58].
Axonal transport also appears to fail early in ALS. This is
suggested by accumulation of ubiquitinated proteins,
phosphorylated neurofilaments, mitochondria and micro-
tubules in proximal axons and anterior horn cells of ALS
patients [83]. Mutations in proteins with axonal functions
are linked to ALS, including SMN, dynactin and spatacsin
[14, 54]. Given that the axon constitutes 99.9% of the
volume of a motoneuron and therefore places great meta-
bolic demands on the cell, it is perhaps unsurprising that
axonal degeneration can be an early event in ALS, and
thus an attractive target for therapeutic intervention.
Almost all ALS and as many as half of FTD cases are
characterised by pathological ubiquitinated inclusions of
TAR DNA-binding protein 43 kDa (TDP-43) [3, 52].
The identification of mutations of TDP-43 in patients
with ALS and FTD demonstrates that TDP-43 plays
mechanistic roles in neurodegeneration [2, 7, 39].
Disturbances in TDP-43 homeostasis have been shown
to affect axonal function and TDP-43 aggregates may
form early within motor axons [10]. Knocking down or
overexpressing wild-type or mutant TDP-43 disrupts
motor neuron axons and terminal arborisations in flies
[16, 42, 44] and zebrafish [38, 41]. TDP-43 transgenic
rodents demonstrate early changes in neuromuscular
junction (NMJ) and axonal integrity [65, 73, 81, 85, 87].
TDP-43 also localises within presynaptic vesicles in mo-
toneurons in human spinal cord [62] and in axons in
vitro [38]. Furthermore, axonal injury causes striking re-
distribution of TDP-43 from the nucleus to the
cytoplasm and axon [50, 63]. Collectively, these results
highlight how aberrant homeostasis of TDP-43 can
directly impair axonal physiology, potentially causing
neurodegeneration.
Given the importance of axon degeneration in ALS,
there has been great interest in trying to protect axons
and synapses as a therapeutic approach. Following injury
to a nerve, typically a cut or crush, the process of
Wallerian degeneration ensues, leading to fragmentation
of axon fibres distal to the injury site within 72 h. This
fragmentation was long thought to be due to loss of
trophic support from the cell body [80], but studies of
the mutant mouse WldS (Wallerian degeneration slow)
established Wallerian degeneration as a tightly regulated
process separate and distinct from apoptosis of the cell
body [46]. While wild-type axons start to degenerate
from 36 h following axotomy, WldS axons remain intact
for weeks and can still conduct action potentials [46].
WldS encodes a fusion protein with nicotinamide
mononucleotide adenylyltransferase 1 (NMNAT1) activ-
ity, which compensates for the loss of the axonal
NMNAT2 isoform, which has a short half-life and is rap-
idly depleted from axonal segments distal to the site of in-
jury or when its supply is interrupted for other reasons
such as axonal transport deficit [13, 25, 47].
Importantly, screening in Drosophila has identified
Wallerian degeneration regulating genes, indicating the
presence of an endogenous axonal auto-destruction
pathway that is conserved in mammals [51, 55, 84]. The
first of these genes to be identified, sterile alpha and TIR
motif-containing 1 (encoding Sarm1), acts downstream
of NMNAT2 loss to promote axon degeneration follow-
ing axotomy [24, 26, 45, 55, 79]. In fact, the deletion of
Sarm1 is significantly more protective than WldS overex-
pression in an Nmnat2 depletion model of neurodegen-
eration as mice age [27]. These observations confirmed
that Wallerian degeneration is an active, genetically
programmed process that can be potently inhibited.
Evidence to suggest that Wallerian-like processes
occur in neurodegenerative diseases comes from recent
studies in which the axon outgrowth and regeneration
factor Stathmin 2 (also known as SCG10) was found to
be downregulated in ALS spinal motor neurons [40, 49].
Loss of Stathmin 2 was previously shown to enhance
Wallerian degeneration following axon transection [66].
Furthermore, impaired axonal mitochondrial function,
an early pathophysiological event in ALS [67], activates
the Wallerian pathway leading to Sarm1-dependent
axonal degeneration [72]. Mechanistic studies have also
shown, to varying degrees, that axonal protection can be
neuroprotective. For example, mice lacking Sarm1 have
improved functional outcomes as well as attenuated
axonal injury following mild traumatic brain injury [31],
while deletion of Sarm1 prevents chemotherapy induced
peripheral neuropathy [23]. WldS can ameliorate axono-
pathy in models of Charcot-Marie-Tooth disease, Par-
kinson’s disease and glaucoma [5, 60, 61]. WldS is also
protective in the progressive motor neuronopathy (pmn)
mouse [18]. Although WldS has little effect on survival
in mutant-SOD1 mice, it significantly protects NMJs in
young G93A transgenic mice [19, 77]. Studies in C. ele-
gans demonstrate that loss of the Sarm1 homolog Tir-1
suppresses neurodegeneration and delays paralysis in-
duced by mutant TDP-43 [78]. Finally, the human
SARM1 locus has also been associated with sporadic
ALS risk [22]. Collectively, these observations suggest
that Wallerian-like mechanisms could contribute to the
neurodegeneration seen in motor neuron diseases, and
that depletion of SARM1 could have therapeutic
potential in ALS. However, there have been no studies
in mammalian models that have investigated a link
between Wallerian pathways and TDP-43-mediated
neurodegeneration. This is a particularly important
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question as TDP-43 pathology is a hallmark of 98% of
ALS, including sporadic ALS. We therefore sought to
determine whether SARM1 signalling could be a thera-
peutic target in ALS by deleting Sarm1 from a TDP-
43Q331K transgenic mouse model of ALS-FTD. Our
results demonstrate that Sarm1 deletion has a neuropro-
tective effect and leads to both improvements in motor
axonal integrity and, importantly, lumbar motor neuron
survival.
Materials and methods
Mouse breeding and maintenance
High expression hTDPQ331K and Sarm1 knock out mice
were acquired from Jackson Laboratories and main-
tained on a C57BL/6Babr background in a 12 h light/
dark cycle with ad libitum access to food and water.
Mice were housed in Tecniplast cages within a clean
facility. Individual cages contained environmental en-
richment items and group sizes of 2–5 mice were
routinely maintained. Transgenic colonies were gener-
ated by breeding male mice heterozygous for both
Sarm1 deletion and TDPQ331K transgenes with Sarm1
heterozygous or null females. Crosses were designed
such that all mice also expressed the Thy1-YFP trans-
gene (see Fig. 1a) (Feng Neuron 2000). Genotyping for
the YFP-H, TDPQ331K and Sarm1 knockout alleles was
performed as described previously [1, 4, 26]. Both male
and female mice were used for experimental studies;
mouse sex and age are highlighted where appropriate.
All animal experiments were performed under the UK
animals (Scientific Procedures) Act 1986 Amendment
Regulations 2012 on Project Licence 70/7620.
Behavioural testing
Motor testing was performed using Rotarod on both
male and female mice (Ugo Basile, Model 7650, Varese,
Italy). At least 24 h prior to testing mice were first
trained for 5 min at the slowest speed and then 7min
with acceleration. During testing mice were subjected to
7 min trials with acceleration from 3.5 to 35 rpm. In each
session mice were tested 3 times with a trial separation
of 30 min. The latency to fall (maximum 420 s) for each
mouse was recorded and mean values for each mouse
calculated. An individual mouse recording was excluded
if it fell off the rod while moving backwards, accidentally
slipped or jumped off at a slow speed. Two consecutive
passive rotations were counted as a fall and the time
recorded as the end point for that mouse. Mouse
weights were recorded immediately after completion of
rotarod testing. All testing was conducted by operators
who were blind to genotype and in a randomised order.
To assess clasping, male mice were suspended by the
base of the tail and observed for 10–15 s. Testing took
place immediately following measurement of weight.
Hindlimb clasping was rated from 0 to 4 based on sever-
ity: 0= hindlimbs splayed outward and away from the
abdomen, 1= one hindlimb partially retracted inwards
towards the abdomen for at least 50% of the observation
period, 2 = both hindlimbs partially retracted inwards
towards the abdomen for at least 50% of the observation
period, 3 = one hindlimb fully retracted inwards towards
the abdomen for at least 50% of the observation period 4
= both hindlimbs fully retracted inwards towards the
abdomen for at least 50% of the observation period.
All marble-burying testing was conducted in the
morning and blind to genotype on both male and female
mice. Cages of size 39.1 cm × 19.9 cm × 16.0 cm height
(Tecniplast) were used. Fresh bedding material (Date-
sand, grade 6) was placed into each cage to a height of
~ 6 cm. Ten glass marbles (1 cm) were placed evenly
across the bedding. Ten cages were prepared in a single
round. One mouse was placed in each of the cages and
the lids replaced. Mice were left undisturbed for 30 min
under white light. Mice were then removed, and the
number of marbles buried by at least two thirds was
scored. Cages were reset using the same bedding
material to test another 10 mice.
Pathological studies
Unless specified, mice were culled by asphyxiation with
CO2 followed by cervical dislocation and tissue extrac-
tion. Brains and gastrocnemius muscles of male and
female mice were weighed. The tissues were then
immersion fixed in 4% paraformaldehyde (PFA) at 4 °C
for 24–48 h, washed in PBS, cryoprotected in 30% su-
crose in PBS to store at 4 °C. For ex vivo MRI studies
animals were anaesthetised and transcardially perfused
with PBS followed by a 4% PFA solution. Heads were re-
moved, scalped and then placed into 4% PFA for at least
24 h. Heads were subsequently rehydrated in PBS with
0.05% sodium azide for at least 14 days prior to MRI
scanning. For lumbar motor neuron quantification tis-
sues were used following transcardial perfusion as above.
YFP-H motor axon quantification
Spinal cords were extracted from vertebral columns and
L4 ventral nerve roots were carefully dissected from
male mice. Following dissection the nerve roots were
treated for wholemount fluorescence preparation using
Vectashield Mounting Medium (Vector Laboratories) as
described previously [6]. Z-stacks of the wholemount
YFP-H axons were obtained using a Nikon A1R Con-
focal Laser Microscope System with a 20x objective. The
number of YFP+ axons per roots, axon diameters and
percentage of fragmentated axons were then measured
using NIS-Elements imaging software blind to genotype.
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Fig. 1 Sarm1 deletion mitigates TDP43Q331K-mediated motor neuron loss and axon degeneration. a. Breeding scheme. b. Nissl-stained lumbar
motor neurons of 10-month-old mice. Representative images shown. Scale bar, 50 μm. c. Quantification of Nissl-stained lumbar motor neurons
per section at spinal cord L3. (n = 4 NTG; n = 4 Q331K-Sarm1+/−; n = 6 Q331K-Sarm1−/−) ANOVA P = 0.0404. Pairwise comparisons: NTG vs. Q331K-
Sarm1+/−: * P = 0.0351; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: * P = 0.0392. d. Representative images showing intact YFP+ axons of L4 ventral roots
from mice of three genotypes at different time points. Scale bar 100 μm. e. Quantification of fluorescent axons in wholemount YFP+ L4 ventral
roots at different time points. ANOVA Interaction P = 0.0157. Pairwise comparisons: 5 weeks, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ** P = 0.0026; 3
months, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ** P = 0.0040; 10 months, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: * P = 0.0289. f. Percentage of YFP+
axons undergoing fragmentation in L4 ventral roots at different time points. ANOVA Genotype P < 0.0001. Pairwise comparisons: 5 weeks, Q331K-
Sarm1+/− vs. Q331K-Sarm1−/−: ** P = 0.0014; 3 months, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.1104; 10 months, NTG vs. Q331K-Sarm1+/−: *
P = 0.0464; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.7870. g. Fibre diameters measured at the thickest part of intact YFP+ axons in L4 ventral
roots at different time points. ANOVA Interaction P = 0.0051. Pairwise comparisons: 5 weeks, NTG vs. Q331K-Sarm1+/−: ns P = 0.1295; Q331K-
Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.2198; 3 months, NTG vs. Q331K-Sarm1+/−: ns P = 0.1567; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.1567;
10 months, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.1810. h. Distribution of diameters of YFP+ L4 motor axons at 10 months of age. ANOVA
Interaction P = 0.0014. Pairwise comparisons: Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: * P = 0.0386. For (e-h) (n = 5 mice per genotype); ****P < 0.0001.
For (c) one-way (e-h) two-way ANOVA followed by Holm-Sidak post-hoc test for pairwise comparisons. Error bars represent mean ± s.e.m
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Quantification of neuromuscular junction innervation
Fixed, cryoprotected gastrocnemius muscles from male
mice were placed in a silicone mould with M1 matrix
(Thermofisher Scientific), and frozen on dry ice. Longi-
tudinal cryosections (50 μm) were mounted onto slides,
air dried at room temperature (R/T) for 5 min and
stored at − 80 °C. To stain neuromuscular junctions
(NMJs), slides were brought up to R/T and incubated in
blocking solution (2% BSA, 0.5% Triton X-100, 0.1%
sodium azide) for 1 h. Primary antibodies against βIII-
tubulin (rabbit polyclonal, Sigma T2200) and synapto-
physin (mouse monoclonal, Abcam ab8049) were
applied at a 1:200 dilution in blocking solution. Sections
were incubated at R/T overnight. Sections were washed
in PBS and incubated for 90 min with mouse and rabbit
Alexa488-conjugated secondary antibodies (Thermo-
fisher Scientific) diluted 1:500 in blocking solution
together with TRITC-conjugated alpha bungarotoxin
(Sigma, T0195). Z-stacks were obtained using an Olym-
pus Whole Slide Scanner (VS120) with a 20x objective.
NMJs from flattened z-stacks of muscle were analysed
blind to genotype. Brightness and contrast thresholds
were set to optimise the signal-to-noise ratio of the pre-
synaptic staining (anti-tubulin and anti-synaptophysin).
To assess the co-localization of pre- and post-synaptic
membrane proteins at the NMJ, 90–110 NMJs were ana-
lysed per animal per genotype for all ages by eye. Fully
innervated NMJs were defined as demonstrating full co-
localization of pre- and post- synaptic staining. Fully
denervated NMJs were defined as alpha-bungarotoxin
signal in the absence of pre-synaptic staining. Partially
innervated NMJs were defined as having partial overlap
of pre- and post-synaptic labelling.
Spinal cord motor neuron Nissl staining
Fixed spinal cords from male mice were sub-dissected,
paraffin embedded and subsequently sectioned (10 μm
thickness) onto charged slides. Sections were initially
dewaxed in xylene followed by rehydration through
graded alcohols and then washed in water. Sections were
stained with cresyl etch violet (0.05%) for 30 min, briefly
washed in 96% ethanol, dehydrated in 100% ethanol,
cleared in xylene, mounted (Permount, Fisher) and dried
overnight at R/T. Images were taken on an EVOS FL
Cell Imaging System (Thermofisher Scientific) using a
20x objective. For motor neuron quantification, Nissl
positive cells of the ventral horn ≥20 μm in diameter
were counted from 7 to 8 sections per mouse to deter-
mine the average count per section.
Cortical neuron quantification
Cyroprotected mouse brains from male mice were em-
bedded and frozen in M1 matrix and sectioned coronally
at 60 μm thickness on a cryostat (Leica Biosystems).
Sections were then mounted on slides and coverslips ap-
plied. Z-stacks were acquired using an Olympus Whole
Slide Scanner (VS120) with a 20x objective. Coronal sec-
tions from flattened z-stacks of brains were analysed
using ImageJ blind to genotype. YFP+ cortical neurons
from primary motor cortex and entorhinal cortex were
measured from matching sections of each mouse from
each genotype. Consistent regions of interest were
drawn around the cortex and cells counted using Visio-
pharm image analysis software (Hoersholm, Denmark).
Cortical dendritic spine analysis
YFP-H fluorescence was captured using the Nikon iSIM
Super Resolution Microscope System running Nikon
Elements software using a GFP filter. We focused on the
distal branches of the apical dendrites 120 μm from the
cell bodies of the neurons in layer V of the motor cortex.
To image apical dendritic spines, a 100x oil objective
was used to acquire z-plane images with 0.8 μm intervals
through 20 μm of tissue. Five images were collected from
the primary motor cortex per animal. To characterise
the apical dendritic spines, z-stack images were analysed
using Neurolucida Explorer software (MBF Bioscience,
USA). Dendrites were traced through stacks with spines
marked, and images then exported to Neurolucida
Explorer for spine quantification. Branched structure
analysis was used to analyse the number of dendritic
spines per μm and density of spines of different morph-
ologies. Spines were classified either as mushroom,
stubby or thin type according to spine neck length and
spine head size, referring to established parameters [30].
Structural magnetic resonance imaging
Ex vivo, in loco MRI was performed for 10-month-old
female mice (n = 32) using a 9.4 T horizontal bore BioS-
pec 94/20 scanner (Bruker). The mouse heads were
placed four at a time in a 50ml Falcon tube filled with
fomblin (Solvay) and scanned overnight using a quadra-
ture birdcage transceiver coil (39 mm internal diameter).
T2-weighted images were acquired using a 3D fast spin-
echo sequence: effective echo time 30 ms, repetition time
3000 ms, field of view 25 × 25 × 20mm, acquisition
matrix 250 × 250 × 200. Diffusion tensor imaging (DTI)
data was acquired using a 2D Stejskal-Tanner spin-echo
sequence: echo time 22.6 ms, repetition time 4000ms,
field of view 25.6 × 25.6 mm, acquisition matrix 256 ×
256, 67 slices with 0.2 mm thickness and 0.1 mm gap, b-
value 1500, 30 diffusion directions, 4 b0 images.
Fractional anisotropy (FA) maps were computed from
the DTI data using dtifit (FSL).
A study-specific template was generated from a subset
of 20 mice (antsMultivariateTemplateConstruction2.sh),
and all brains were then registered to the template
(antsRegistrationSyN.sh). Jacobian determinant maps of
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the deformation matrices were computed and log-trans-
formed to perform voxel-wise nonparametric statistics
(FSL randomise, 5000 permutations, threshold-free clus-
ter enhancement) to compare local brain volumes be-
tween NTG, Q331K-Sarm1+/−, and Q331K-Sarm1−/−
mice.
To perform region-of-interest (ROI) analysis, the
study-specific template was registered to the DSURQE
mouse brain atlas (Mouse Imaging Centre, Toronto),
which consists of 28 bilateral and 154 unilateral ROIs
(336 total). These labels were transformed to the study-
specific template space, and the volume of each ROI in
each mouse was calculated. DSURQE mouse brain atlas
can be accessed at: https://wiki.mouseimaging.ca/dis
play/MICePub/Mouse+Brain+Atlases#MouseBrainA-
tlases-Dorr-Steadman-Ullmann-Richards-Qiu-Egan(40
μm,DSURQE).
Randomisation
The order and genotype of animals and samples tested
was randomized by one operator before subsequent
experimental studies were conducted by a second
investigator.
Experimental design and statistical analysis
Experimental data were conducted by researchers
blinded to the genotype of animals. Statistical analyses
were conducted using Prism 8.1.2 (GraphPad). Graphs
were plotted using GraphPad. Use of parametric tests
required data to be sampled from a Gaussian distri-
bution. Homogeneity of variance between experimen-
tal groups was confirmed by the Browne-Forsythe test
for ANOVA. For comparisons between genotypes or
experimental groups, one-way or two-way ANOVA
was used. Multiple comparisons by ANOVA were
corrected using the Holm–Sidak test. All statistical
comparisons are based on biological replicates unless
stated otherwise. Where technical replication of ex-
periments occurs, this is highlighted in the respective
method. Behavioural testing by rotarod and hind limb
clasping as well as weight were analysed by Mixed-ef-
fects analysis with Geisser-Greenhouse correction
followed by Holm-Sidak multiple comparison test.
Unless stated otherwise, all charts show mean ± s.e.m.
and statistical tests used are described in the relevant
results or figure legends. P-values < 0.05 were consid-
ered significant for all statistical analyses used.
Data availability
The authors will make all data available to readers upon
reasonable request.
Results
Sarm1 deletion significantly reduces TDP-43Q331K-
mediated motor neuron degeneration
To determine whether Sarm1 deletion could attenuate
TDP-43-mediated neurotoxicity we designed a crossing
scheme to knock out Sarm1 from a transgenic mouse
model of ALS that overexpresses human mutant TDP-
43Q331K under the mouse prion promoter [4]. The cross
was designed such that all study mice and littermate
controls were also transgenic for YFP-H to facilitate
visualisation of central and peripheral neuronal struc-
tures [6, 17]. As Sarm1+/− mice show no significant
protection from Wallerian degeneration at 5d or more
post-lesion [55] we used TDP-43Q331K-Sarm1+/− as
controls for TDP-43Q331K-Sarm1−/−, so that littermate
controls could be used without requiring excessively
large breeding numbers (Fig. 1a). The study proceeded
using three genotypic groups of mice, analysing males
and females separately: TDP-43Q331K, Sarm1+/−, YFP-H
(hereon referred to as Q331K-Sarm1+/−), TDP-43Q331K,
Sarm1−/−, YFP-H (Q331K-Sarm1−/−), and Sarm1+/−,
YFP-H mice with no TDP-43Q331K transgene (NTG).
To examine if Sarm1 deletion significantly reduces
TDP-43Q331K-mediated motor neuron degeneration,
Nissl stained cells of the ventral horn greater than 20 μm
in diameter were counted (Fig. 1b, c). TDP-43Q331K
overexpression caused significant motor neuron loss at
10 months of age, reducing numbers by 46% in Q331K-
Sarm1+/− mice compared to NTG mice (p = 0.0351).
However, this loss was significantly attenuated in
Q331K-Sarm1−/− mice (p = 0.0392), which demonstrated
64% more motor neurons than Q331K-Sarm1+/− mice
(only 11% below the numbers observed in NTG mice).
This indicates that Sarm1 deletion significantly reduces
motor neuron degeneration caused by TDP-43Q331K.
Sarm1 deletion mitigates TDP43Q331K-mediated motor
axon degeneration
To examine if enhanced motor neuron survival was also
associated with preservation of motor axons, a longitu-
dinal histological evaluation was performed by exploiting
the sparse labelling of neurons by YFP-H in L4 ventral
nerve roots. Intact and fragmented YFP positive (YFP+)
axons within the L4 ventral nerve root were quantified
at 5 weeks, 3 months and 10 months of age (Fig. 1d-f).
While NTG mice demonstrated ~ 30–40 YFP+ motor
axons at all time points, with no axons demonstrating
fragmentation, Q331K-Sarm1+/− mice demonstrated
only ~ 20 YFP+ axons, ~ 21% of which were fragmented
as early as 5 weeks of age (Fig. 1e, f). Furthermore, the
number of intact axons in Q331K-Sarm1+/− mice re-
duced significantly over time, indicating progressive,
age-related axon degeneration due to TDP-43Q331K
expression. However, in Q331K-Sarm1−/− mice axon
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loss was significantly attenuated at all ages tested, and
early fragmentation was reduced by 67% at 5 weeks
when compared to Q331K-Sarm1+/− mice (p = 0.0014)
(Fig. 1e, f). We also assessed the diameter of remaining
unfragmented YFP+ axons within the L4 ventral nerve
root. At 10 months of age, the mean axon diameter was
significantly reduced in the Q331K-Sarm1+/− mice by
27% compared to NTG (p < 0.0001) (Fig. 1g), and this
was partially attenuated in Q331K-Sarm1−/− mice (p =
0.0386) (Fig. 1h). Collectively, these results indicate that
Sarm1 deletion partially protects motor axons from the
neurodegenerative effects of human mutant TDP-
43Q331K.
Sarm1 deletion reduces TDP-43Q331K-mediated NMJ
degeneration
Previous studies have shown that deletion of Sarm1
preserves NMJ integrity for several days following
peripheral nerve transection [55]. We therefore assessed
whether Sarm1 deletion afforded similar protection
against TDP-43Q331K-mediated NMJ degeneration
(Fig. 2a-d). At 5 weeks of age NMJ innervation in gastro-
cnemius muscles of TDP-43Q331K mice was considerably
lower than in NTG mice, indicating that TDP-43Q331K
causes very early and severe denervation (p < 0.0001)
(Fig. 2b). Innervation patterns were comparable between
Q331K-Sarm1+/− and Q331K-Sarm1−/− mice at 5 weeks
of age, but at 3 months of age Q331K-Sarm1−/− mice
demonstrated 45% fewer denervated NMJs (p = 0.0124)
and 58% more fully-innervated NMJs (p = 0.0032) than
Q331K-Sarm1+/− mice (Fig. 2b, c). By 10 months of age
the percentage of denervated NMJs was still significantly
reduced in Q331K-Sarm1−/− mice compared to Q331K-
Sarm1+/− mice (p = 0.0030), and there was a trend
towards an increase in partially innervated NMJs (p =
0.0711) (Fig. 2d). To determine if these improvements in
NMJ innervation influenced muscle bulk, gastrocnemius
muscle weights were compared. Male TDP-43Q331K mice as
young as 5 weeks of age showed significant muscle weight
loss, which progressed with age (Additional file 1a). In
Fig. 2 Sarm1 deletion reduces TDP-43Q331K-mediated NMJ degeneration. a. Representative images of immunofluorescent staining of NMJs in the
gastrocnemius muscle from mice at different time points (Green = synaptophysin and β-III-tubulin co-stain, Red = α-bungarotoxin). Scale bar,
50 μm. (b-d) Percentages of fully innervated, partially innervated, and denervated NMJs in the gastrocnemius muscles of each genotype at
different time points. b. At 5 weeks, ANOVA Interaction P < 0.0001. Pairwise comparisons: Fully innervated, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns
P = 0.0520; Partially innervated, NTG vs. Q331K-Sarm1+/−: ** P = 0.0027; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.5852; Denervated, NTG vs.
Q331K-Sarm1+/−: ** P = 0.0024; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.1107. c. At 3 months: ANOVA Interaction P < 0.0001. Pairwise
comparisons: Fully innervated, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ** P = 0.0032; Partially innervated, NTG vs. Q331K-Sarm1+/−: *** P = 0.0004;
Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.5585; Denervated, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: * P = 0.0124. d. At 10 months: ANOVA
Interaction P < 0.0001. Pairwise comparisons: Fully innervated, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.1949; Partially innervated, Q331K-
Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.0711; Denervated, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ** P = 0.0030. For (b-d) (n = 5 mice per genotype);
****P < 0.0001; two-way ANOVA followed by Holm-Sidak post-hoc test for pairwise comparisons. Error bars represent mean ± s.e.m
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females, significant muscle loss was only observed in TDP-
43Q331K mice at 15months of age (Additional file 1b).
However, no significant differences in muscle weight were
seen between Q331K-Sarm1+/− and Q331K-Sarm1−/− mice,
indicating that the improvement in NMJ innervation due to
Sarm1 deletion was not enough to influence muscle
atrophy caused by TDP-43Q331K.
TDP-43Q331K-mediated cerebral atrophy and cortical
neuronal loss are not suppressed by Sarm1 deletion
ALS overlaps clinically, pathologically and genetically
with FTD, which is characterised by atrophy of the
temporal as well as the frontal lobes of the brain. We
therefore examined the brains of our mice to determine
if TDP-43Q331K overexpression and/or Sarm1 play a role
in neurodegeneration of cerebral structures. An examin-
ation of whole brains from both male and female mice
was performed. This demonstrated a significant loss of
brain mass in male Q331K-Sarm1+/− and Q331K-
Sarm1−/− mice compared to NTG from early timepoints
(6% at 5 weeks, 5% at 3 months, and 8% at 10 months of
age, Fig. 3a). Significant brain weight loss in females was
only seen at 15 months of age (Fig. 3b). No significant
differences were seen between Q331K-Sarm1+/− and
Q331K-Sarm1−/− mice, suggesting that Sarm1 deletion
does not suppress gross brain atrophy secondary to
TDP-43Q331K. However, measuring total brain weights
may not be a sensitive enough method to find subtle
differences in brain weight, and cannot be used to iden-
tify regional volume loss. We therefore conducted an ex
vivo, in loco brain magnetic resonance imaging (MRI)
study in a separate group of female mice. This analysis
confirmed that both the Q331K-Sarm1+/− (505 ± 4mm3)
and Q331K-Sarm1−/− mice (508 ± 3mm3), had signifi-
cantly smaller brains than the NTG mice (534 ± 5mm3),
and also found no significant difference in total brain
volumes between Q331K-Sarm1+/− and Q331K-
Sarm1−/− mice (Fig. 3c).
Further analyses of the MRI data were performed to
identify region-specific effects of TDP-43Q331K and Sarm1
deletion by measuring regional brain volumes and
diffusivity parameters (Fractional Anisotropy (FA) and
mean diffusivity (MD)) (Fig. 3d, e, Additional file 2a,b,
Additional file 5: Table S1). We observed prominent
decreases in regional brain volumes primarily located in
temporal-equivalent and hippocampal regions of the
brain, which were accompanied by much smaller changes
in FA and no significant effects on MD (Fig. 3d, e,
Additional file 5: Table S1). A Region of Interest
(ROI) analysis compared in more detail the changes
in volume and FA in specific brain regions as out-
lined in the DSURQE mouse atlas (Additional file 5:
Table S1). Significantly reduced volume was observed
in several areas including the insular region (6.77%),
dorsolateral entorhinal cortex (11.65%), perirhinal cor-
tex (14.04%), amygdala (9.7%), hippocampal CA3
(6.69%), and pre-para subiculum (7.77%) in Q331K-
Sarm1+/− mice compared to NTG mice. This indi-
cates that the greatest brain volume loss occurred
preferentially in temporal lobe-equivalent regions of
TDP-43Q331K mice (Additional file 2a). Decreased FA
was observed in several white matter tracts including
the anterior commissure (4.1%), stria terminalis (3.2%)
internal capsule (1.1%) and facial nerve (3.5%), while
several grey matter temporal regions showed an increase
in FA including the ectorhinal cortex (2.11%), perirhinal
cortex (1.68%), and insular region (3.00%) in Q331K-
Sarm1+/− mice (Additional file 5: Table S1). Overall, how-
ever, there were no significant regional differences in brain
volume or FA between Q331K-Sarm1+/− and Q331K-
Sarm1−/− mice (Additional file 2b).
To investigate the cellular cause of the changes ob-
served with MRI in TDP-43Q331K mice, YFP-expressing
neurons in the cortex were counted. Neuronal numbers
were significantly decreased (p = 0.0009) in the entorhi-
nal cortex of Q331K-Sarm1+/− mice, which contrasts
with no significant loss of neurons in the motor cortex
(Fig. 3f, g). Neuron numbers were not significantly dif-
ferent between Q331K-Sarm1+/− and Q331K-Sarm1−/−
mice in either brain region. Collectively, these studies
demonstrate that Sarm1 deletion does not influence re-
gional brain atrophy or neuronal loss caused by TDP-
43Q331K, and that temporal-lobe equivalent brain regions
are more significantly affected by TDP-43Q331K overex-
pression than the primary motor cortex.
TDP-43Q331K-mediated dendritic spine defects in the
motor cortex are suppressed by Sarm1 deletion
Synaptic degeneration and dendritic spine loss are an
early feature of neurodegenerative conditions including
dementias [32]. TDP-43 plays a crucial role in the for-
mation and turnover of dendritic spines, as manipulation
of TDP-43 expression causes significant changes in spine
morphology and density in cortical neurons [21, 29, 33].
SARM1 also regulates synaptic plasticity and dendritic
spine growth [11, 43]. Although our studies of the brain
demonstrated that TDP-43Q331K-induced cortical atro-
phy and neuronal loss were not suppressed by Sarm1
deletion, we hypothesised that Sarm1 deletion could still
mitigate dendritic spine loss in mutant mice. We there-
fore examined spine density and shape in layer V of the
motor cortex in TDP-43Q331K and NTG mice, focussing
specifically on distal branches of apical dendrites, as they
form abundant arbours rich in spines (Fig. 4a). TDP-
43Q331K expression reduced spine density to only 45%
that of NTG mice (p = 0.0014) but this was significantly
improved in Q331K-Sarm1−/− mice to 78% of NTG (p =
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0.0268) (Fig. 4b). Analyses of individual spine volume
and surface area demonstrated no significant differences
between any genotypes (Additional file 3a,b). Morpho-
logically, dendritic spines can be classified into three
main subsets: thin, stubby, and mushroom [34, 68].
While thin spines are usually transient with a rapid turn-
over, mature stubby and mushroom spines establish
stable connections [9, 35]. To determine if the alter-
ations in dendritic spine densities were associated with
specific morphological subsets, we calculated the density
of thin, stubby, or mushroom shaped spines (Fig. 4c-e).
The density of thin spines in Q331K-Sarm1+/− mice was
reduced to 38% that of NTG mice (p = 0.0034), while
stubby and mature spines were not significantly altered.
However, Q331K-Sarm1−/− mice demonstrated a higher
density of thin spines, reaching 81% of the density seen
in NTG mice (p = 0.0227). Collectively, these results
indicate that Sarm1 deletion significantly suppresses
Fig. 3 (See legend on next page.)
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dendritic spine loss caused by TDP-43Q331K, preferen-
tially maintaining a population of thin spines.
Sarm1 deletion attenuates the pre-weaning loss of male
TDP-43Q331K mice but does not influence age-related
behavioural impairments
Having determined that Sarm1 deletion ameliorated
TDP-43Q331K-induced motor neuron degeneration and
dendritic spine loss we bred larger cohorts of mice for
behavioural studies. During breeding we found that
female mice surviving to at least 10 days of age were
present at Mendelian ratios (Fig. 5a). However, fewer
males survived to this age carrying the TDP-43Q331K
transgene than would be expected by Mendelian inherit-
ance laws (44%, 54/124). In contrast, a higher-than-ex-
pected proportion of male mice survived that were
Sarm1−/− (61%, 76/124), and more specifically, a signifi-
cant majority (63%, 34/54) of males with a TDP-43
transgene were Sarm1−/−. This suggests that successful
embryonic and/or early post-natal development of male
offspring is inhibited by TDP-43Q331K overexpression,
and that this effect is mitigated by Sarm1 deletion.
To determine if Sarm1 signalling contributes to behav-
ioural deficits caused by TDP-43Q331K motor function
was assayed using Rotarod. From 3months of age all
male TDP-43Q331K mice demonstrated a progressive
decline in motor performance compared to their NTG
littermates, however, no significant difference was seen
between Q331K-Sarm1−/− and Q331K-Sarm1+/− mice
(Fig. 5b). Interestingly, TDP-43Q331K mice gained signifi-
cantly more weight than NTG littermates from as early
as 3 months of age. Again, no significant difference was
seen between Q331K-Sarm1−/− and Q331K-Sarm1+/−
male mice (Fig. 5c). Similar observations were made in
female mice (Additional file 4a, b). Given that weight
gain is likely to impair Rotarod performance, weight-in-
dependent motor deficits in males were measured by
hindlimb clasping, which is thought to be a measure of
spastic motor impairment [36, 86]. From 3 months of
age, greater clasping was observed in TDP-43Q331K com-
pared to NTG mice with no difference seen between
Q331K-Sarm1−/− and Q331K-Sarm1+/− mice (Fig. 5d).
To examine cognitive function we used the marble-bury-
ing assay, a measure of innate digging behaviour [74,
82]. Up to 7 months of age, NTG mice buried over 75%
of marbles. However, Q331K-Sarm1+/− mice demon-
strated significantly attenuated digging behaviour with
only ~25% of marbles being buried from as early as 3
months of age, and declining further by 7 months of
age, indicating striking cognitive impairment (Fig. 5e).
This deficit was not reversed by Sarm1 deletion. Collect-
ively, these results indicate that TDP-43Q331K causes
early and prominent changes in weight, motor and cog-
nitive performance, which are not attenuated by Sarm1
deletion.
Discussion
Here, we have shown that by deleting Sarm1 from a
TDP-43Q331K transgenic mouse model of ALS-FTD it is
possible to significantly attenuate motor axon, NMJ and
motor neuron cell body degeneration. Sarm1 deletion
appeared to protect motor neuron cell bodies to a greater
extent than motor axons, which were in turn protected
more so than NMJs (compare Fig. 1c, e and 2c). An
underlying mechanism for this could be that motor neu-
rons are reliant on neurotrophic support from distal tar-
gets of innervation for continued survival [59, 64, 76]. By
preserving the physical link between the cell body and the
target muscle, Sarm1 deletion may improve cell body sur-
vival by helping to maintain retrograde trophic support.
(See figure on previous page.)
Fig. 3 Neurodegeneration is more prominent in the entorhinal cortex than motor cortex of TDP-43Q331K mice. a-b. Brain weights of mice at
different time points. a. Male (n = 6–8 NTG; n = 4–6 Q331K- Sarm1+/−; n = 6–10 Q331K-Sarm1−/−). ANOVA genotype P < 0.0001. Pairwise
comparisons: 5 weeks, NTG vs. Q331K-Sarm1+/−: * P = 0.0160; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.5696; 3 months, NTG vs. Q331K-
Sarm1+/−: * P = 0.0458; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.9658; 10 months, NTG vs. Q331K-Sarm1+/−: **** P < 0.0001; Q331K-Sarm1+/−
vs. Q331K-Sarm1−/−: ns P = 0.6290. b. Female (n = 5–8 NTG; n = 3–5 Q331K-Sarm1+/−; n = 4–5 Q331K-Sarm1−/−). ANOVA genotype P = 0.0006.
Pairwise comparisons: 1 month, NTG vs. Q331K-Sarm1+/−: ns P = 0.3873; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.3283; 4 months, NTG vs.
Q331K-Sarm1+/−: ns P = 0.4957; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.8347; 15 months, NTG vs. Q331K-Sarm1+/−: * P = 0.0279; Q331K-
Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.5565. c. Brain volumes of female mice at 10 months of age measured by ex vivo MRI (n = 11 NTG; n = 10
Q331K-Sarm1+/−; n = 11 Q331K-Sarm1−/−). ANOVA P < 0.0001. Pairwise comparisons: NTG vs. Q331K-Sarm1+/−: *** P = 0.0001; Q331K-Sarm1+/− vs.
Q331K-Sarm1−/−: ns P = 0.6180. d-e. MRI study-specific template (d. coronal; e. transverse) with an overlay representing voxel-wise volume
differences (%) between Q331K-Sarm1+/− and NTG mice at 10 months of age. The colour of the overlay indicates the inter-group volume
difference (warm and cool colours represent gain and loss of volume, respectively, ranging from − 25 to 25%), while the transparency indicates
the statistical significance, ranging from FWE-corrected p value 0.5 (transparent) to 0 (opaque). Areas in which FWE-corrected p value < 0.05 are
contoured in black. (Red arrow – entorhinal cortex; yellow arrow – cingulate cortex) f-g. Representative images of YFP+ neurons from the primary
motor cortex (upper) and entorhinal cortex (lower) from mice 10 months of age. Scale bar 200 μm. f. Density of YFP+ neurons in both the
primary motor and entorhinal cortex (n = 5 NTG; n = 4 Q331K-Sarm1+/−; n = 5 Q331K-Sarm1−/−). YFP+ neuron density motor cortex: ANOVA P =
0.2661. YFP+ neuron density entorhinal cortex: ANOVA P = 0.0013, Pairwise comparisons: NTG vs. Q331K-Sarm1+/−: *** P = 0.0009; Q331K-Sarm1+/−
vs. Q331K-Sarm1−/−: ns P = 0.1079. (a-b) Two-way (c, g) one-way ANOVA followed by Holm-Sidak post-hoc test for pairwise comparisons; error
bars represent mean ± s.e.m
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Collectively, these findings are in keeping with the hypoth-
esis that ALS is a dying-back disease in which the most
distal compartments of motor neurons (the NMJs and
axons) are the most vulnerable in disease.
Importantly, our study design used Sarm1 hemizygos-
ity to enable comparison with littermate controls with-
out the need for an excessively large breeding program.
The inability of Sarm1 hemizygosity to preserve severed
sciatic nerves for up to 2 weeks supports this approach.
However, it cannot be ruled out that Sarm1 hemizygos-
ity is partially protective in some circumstances. This
raises the possibility that in the present study we may be
underestimating the protective capacity of Sarm1 dele-
tion as we did not utilise mice that were Sarm1+/+ as
controls.
This study used a TDP-43Q331K transgenic mouse pre-
viously described as a model of ALS [4]. Interestingly,
we observed several characteristics that were not previ-
ously reported for this model and which are reminiscent
of FTD. We noted that TDP-43Q331K mice gained sig-
nificant weight compared to NTG mice. Mutants were
also strikingly cognitively impaired and demonstrated
Fig. 4 TDP-43Q331K-mediated dendritic spine defects in the motor cortex are partially suppressed by Sarm1 deletion. a. Representative images of
the Thy1-YFP motor cortex apical dendrites from Layer V cortical neurons (upper), and the corresponding Neurolucida tracing (middle; Red = thin
spine, Pink = stubby spine, Blue =mushroom spine) from mice of each genotype at 10 months of age. Scale bar, 5 μm. Examples of different spine
morphologies (lower) [28]. b. Density of apical dendritic spines per micrometre in motor cortex. ANOVA P = 0.0016. Pairwise comparisons: NTG vs.
Q331K-Sarm1+/−: ** P = 0.0014; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: * P = 0.0268. (c-e) Spines were classified either as mushroom, stubby or thin
type according their morphologic features. Density of each type of apical dendritic spines per millimetre in motor cortex. c. Thin spine density:
ANOVA P = 0.0034. Pairwise comparisons: NTG vs. Q331K-Sarm1+/−: ** P = 0.0034; Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: * P = 0.0227. d. Stubby
spine density E. Mushroom spine density. For (b-e) (n = 5 mice per genotype); one-way ANOVA followed by Holm-Sidak post-hoc test for pairwise
comparisons; error bars represent mean ± s.e.m
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significant brain atrophy from an early stage. No weight
gain or cognitive dysfunction was previously described
in this mouse model [4]. These differences could be
because mice bred for this study were on a different
background to that previously described. Although food
intake was not measured, the excessive weight gain that
mutants displayed could be due to hyperphagia, which is
a feature of human FTD, and which we previously described
in TDP-43Q331K knock-in mice [82]. It also remains possible
that this weight gain is due to direct effects of TDP-43
overexpression on lipid metabolism [12, 70].
In keeping with findings in humans, MRI demon-
strated prominent brain atrophy in areas corresponding
to the temporal lobe in these mice, and we histologically
corroborated a greater neuronal loss in the entorhinal
cortex than in the motor cortex. This is interesting, be-
cause studies in humans have shown that the temporal
lobe can be significantly affected in ALS patients even
without clinical evidence of dementia or temporal lobe-
specific dysfunction (Loewe et al. Sci Rep 2017). While
this study found no evidence of changes in MD,
decreased FA was detected in several white matter tracts
further matching the tractography findings in human pa-
tients [56]. Small but significant increases in FA in the
temporal grey matter regions that also feature volume
loss are difficult to interpret, but may be linked to a
combination of alterations in glial and fibre density [71].
Collectively, these observations suggest that this TDP-
43Q331K transgenic mouse recapitulates features of FTD
as well as ALS.
Of particular relevance to FTD, mutant TDP-43 has
previously been shown to cause cortical dendritic spine
abnormalities that are associated with attenuated neur-
onal transmission [21, 29]. In keeping with this, our
study revealed significant brain atrophy and dendritic
spine loss in TDP-43Q331K mice. Furthermore, our study
is the first to demonstrate that this dendritic spine
degeneration can be mitigated by deletion of Sarm1.
Fig. 5 Sarm1 deletion attenuates the pre-weaning loss of male TDP-43Q331K mice but does not influence age-related behavioural impairments.
a. Ratios of mice genotyped at birth (all of which were successfully weaned) broken down by gender. Female (χ2 = 0.289, d.f. = 3, P = 0.962), Male
(χ2 = 8.387, d.f. = 3, P = 0.039); Chi square test. b. Latency to fall of male transgenic mice on accelerating rotarod (n = 5–10 NTG; n = 4–8 Q331K-
Sarm1+/−; n = 6–13 Q331K-Sarm1−/− mice per genotype). Fixed effects (Age x Genotype) P < 0.0001. Pairwise comparisons: Q331K-Sarm1+/− vs.
Q331K-Sarm1−/−: ns P = 0.6873. c. Weights of male mice (n = 4–10 NTG; n = 4–8 Q331K-Sarm1+/−; n = 13 Q331K-Sarm1−/− mice per genotype).
Fixed effects (Age x Genotype) P = 0.0113. Pairwise comparisons: Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.8984. d. Score of male mice on
hindlimb clasping test (n = 5–10 NTG; n = 4–8 Q331K-Sarm1+/−; n = 3–13 Q331K-Sarm1−/− mice per genotype). Fixed effects (Age x Genotype) P =
0.0003. Pairwise comparisons: Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.0764. For (b-d) Mixed-effects analysis followed by Holm-Sidak post-hoc
test for pairwise comparisons. e. Number of marbles buried at different ages (n = 7–12 NTG; n = 4–9 Q331K-Sarm1+/−; n = 7–18 Q331K-Sarm1−/−
mice per genotype). ANOVA Genotype P < 0.0001. Pairwise comparisons: 3–4 months, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P = 0.4154; 5–7
months, Q331K-Sarm1+/− vs. Q331K-Sarm1−/−: ns P > 0.9999. Two-way ANOVA followed by Holm-Sidak post-hoc test for pairwise comparisons. For
(b-e) ****P < 0.0001; error bars represent mean ± s.e.m
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This is notable as Wallerian and Wallerian-like degener-
ation has only previously been linked with axonal, NMJ
and post-synaptic integrity. Our results now suggest that
Wallerian pathways are relevant to post-synaptic com-
partments of neurons, although it is also possible that
the increase in dendritic spines following Sarm1 deletion
is secondary to the preservation of presynaptic nerve ter-
minals that synapse onto the spines.
Interestingly, TDP-43Q331K overexpression pheno-
types show evidence of sexual divergence. This comes
from the observation that during breeding, mutant
mice were underrepresented amongst males but not
females. This is in keeping with our previous observa-
tions in TDP-43Q331K knock-in mice, in which mutant
males but not females were present at a lower fre-
quency than would be expected by Mendelian laws of
inheritance [82]. These phenomena are also more
generally consistent with the higher incidence of ALS
in male patients [48, 75]. Furthermore, we also found
that amongst males there were significantly more
Q331K-Sarm1−/− mice than Q331K-Sarm1+/− mice
(Fig. 1b). This suggests that TDP-43Q331K influences
nervous system development in a way that is attenu-
ated by Sarm1 deletion. We speculate that this bene-
ficial effect of Sarm1 deletion may occur in utero by
influencing Wallerian-like degeneration in a manner
similar to that observed during the rescue of CNS
nerve tracts and peripheral nerve axons in embryos
lacking Nmnat2 [26].
Despite the suppression of neurodegeneration by
Sarm1 deletion, this was insufficient to cause behav-
ioural improvements in TDP-43Q331K overexpressing
mice. This could be because this mouse model demon-
strated very early and marked brain and muscle atrophy,
which may be difficult to reverse. A similar explanation
may underlie the apparent lack of efficacy of Sarm1 de-
letion in a mutant SOD1 mouse model of ALS, which
demonstrates rapid disease onset and progression [57],
and in our previous study in Drosophila in which even
clonal TDP-43Q331K overexpression causes early and ag-
gressive neurodegeneration [69]. We speculate that
under less extreme degrees of cellular disintegration,
and in more physiological models, which are likely to be
more reflective of early disease states in patients with
ALS-FTD, Sarm1 deletion may have a greater ability to
attenuate behavioural and motor dysfunction. Further
support of this comes from human genome-wide studies
that have identified an association between genetic vari-
ants at the human SARM1 locus and the risk of develop-
ing ALS [22]. It remains to be determined if these
genetic variants influence SARM1 expression, but if so
then this would further support a mechanistic link
between TDP-43-mediated toxicity in sporadic ALS and
Wallerian-like degeneration.
Conclusions
In conclusion, our results indicate that a Sarm1
dependent pathway contributes to TDP-43Q331K-medi-
ated motor neuron, motor axon, NMJ and cortical spine
degeneration in vivo. Anti-SARM1 therapies therefore
have potential as a treatment for diseases of the ALS-
FTD spectrum.
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